← SynDRA
2W4
SynDRA canonical compound SYN1627535 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | FASN |
|---|
| Mechanism of action | fatty acid synthase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- FASN INHIBITOR
- fatty acid synthase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Cross-references
Synonyms
- CPD 2
- GSK 2194069
- GSK2194069
- Gsk2194069
- RefChem:922549
- GSK-2194069
- GTPL8605
- orb1707243
- SCHEMBL2356163
- AQTPWCUIYUOEMG-INIZCTEOSA-N
- BDBM119133
- GLXC-05282
- HDC33108
- EBC-14801
- EX-A14228
- NSC792955
- AKOS025147345
- CS-3324
- NSC-792955
- NCGC00387475-02
- NCGC00387475-03
- NCGC00387475-04
- NCGC00387475-06
- DA-53717
- HY-12325
- MS-27586
- GSK2194069 (2)
- EN300-203336
- T15429
- US8802864, 1
- GSK2194069, >=97% (HPLC)
- 4-[4-(1-benzofuran-5-yl)phenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
- HMS3868J13
Look up 2W4 in the interactive SynDRA portal →